RxDoctor Payments Data

Victor Masi, DO

Internal Medicine · Brooklyn, NYNPI 1992705602

Payments from drug & device makers

$1,442in general payments, 2019–2025

Across 76 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$314
  • Lilly USA, LLC$206
  • Merck$178
  • Novartis$116
  • Boehringer Ingelheim$77
  • Pfizer$74
  • plus $477 from 12 others

What the payments were for

  • Food & beverage$1,40097%
  • Education$423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,442 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$233,453
Medicare patients
362
Services billed
3,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate61$74,969
OzempicSemaglutide55$61,229
EliquisApixaban52$55,579
XareltoRivaroxaban60$50,590
JanumetSitagliptin Phos/Metformin Hcl20$32,352
TrulicityDulaglutide23$28,839
Tresiba Flextouch U-200Insulin Degludec33$25,933
FarxigaDapagliflozin Propanediol21$18,920
MounjaroTirzepatide17$17,883
TradjentaLinagliptin20$17,090
JardianceEmpagliflozin11$16,940
Diflorasone Diacetate16$8,697
Butalbital-AcetaminophenButalbital/Acetaminophen11$6,255
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide153$5,733
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$178$107,32281 claims
Novo NordiskOzempic$32$61,22955 claims
PfizerEliquis$74$55,57952 claims
Johnson & JohnsonXarelto$46$50,59060 claims
Lilly USA, LLCTrulicity, Mounjaro$206$46,72340 claims
Boehringer IngelheimTradjenta, Jardiance$77$34,03031 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$2,984214 claims
AbbVieSynthroid$71$2,69236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →